3 documents found, page 1 of 1
Chronic obstructive pulmonary disease exacerbations' management in Portuguese h...
Moita, J.; Brito, U.; Rodrigues, C.; Ferreira, L.; Vieira, J. R.; Catarino, A.; Morais, A.; Hespanhol, V.; Cordeiro, C. R.Introduction and Objectives: In order to improve the quality of chronic obstructive pulmonary disease (COPD) patients' care, better knowledge of clinical practice and the factors associated with patient outcomes are needed. This study aimed to evaluate the relation between clinical practice and the outcomes of patients admitted for COPD exacerbations in Portuguese hospitals. Materials and Methods: Observational...
108P PICTuRE: Real-world treatment pathways in stage III non-small cell lung ca...
Teixeira, M.E.; Oliveira Fernandes, M.G.; Ferreira, M.L.S.; Estevinho, F.; Lopes, J.A.; Araújo, A.; Pacheco Figueiredo, M.M.; Barradas Lopes, M.L.Stage III NSCLC is a heterogeneous and complex setting that requires multimodal management. Recent advances in modern medicine led to the implementation of immuno-oncology (IO) into clinical practice. PICTuRE aims to assess the clinical management and the IO impact on clinical outcomes in stage III NSCLC patients (pts).
Real-world data from the Portuguese Nivolumab Expanded Access Program (EAP) in ...
Figueiredo, A.; Almeida, M.A.; Almodovar, M.T.; Alves, P.; A, Araujo; Araújo, D.; Barata, F.; Barradas, L.; Barroso, A.; Brito, U.; Camacho, E.Objective: The main aim of the study was to evaluate the efficacy and safety profile of Nivolumab, an immune-checkpoint-inhibitor antibody, in advanced, previously treated, Non-Small Cell Lung Cancer (NSCLC) patients, in a real world setting. Methods: We performed a retrospective, multicentre data analysis of patients who were included in the Portuguese Nivolumab Expanded Access Program (EAP). Eligibility crite...